Clinical Trial

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 11, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) plus Eribulin compared to the efficacy and safety of Eribulin monotherapy in the treatment of adult patients with recurrent, or metastatic triple negative breast cancer. The primary study hypothes is that the combination of Cadonilimab (AK104) plus Eribulin is superior to Eribulin monotherapy with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the Investigator.
Trial Details
NCT Number NCT06202313
Lead Sponsor Shengjing Hospital
Conditions Triple Negative Breast Cancer
Enrollment 128 participants
Start Date 2024-02-10
Primary Completion 2025-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-01-11